Inventiva Resumes Trading on Euronext Paris

Inventiva has announced the resumption of trading of its ordinary shares on Euronext Paris, effective June 2, 2026, at 3:30 p.m. CEST. Trading was initially halted at the company's request earlier the same day in light of a Debt Financing Transaction and an Offering of American Depositary Shares in the United States. Each American Depositary Share represents one new ordinary share of Inventiva, with a nominal value of €0.01.

Inventiva is a clinical-stage biopharmaceutical company focusing on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH). Resumption of trading marks a significant step following recent strategic financial maneuvers. The company's stock is traded on Euronext Paris and the Nasdaq Global Market under the ticker symbol IVA.